1. Home
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
Progressive Fibrosing Interstitial Lung Disease (pfild) - Epidemiology Forecast - 2032

Progressive Fibrosing Interstitial Lung Disease (pfild) - Epidemiology Forecast - 2032

  • August 2022
  • 90 pages
  • ID: 6316451
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Progressive Fibrosing Interstitial Lung Disease (PF-ILD)- Epidemiology Forecast–2032’ report delivers an in-depth understanding of the Progressive Fibrosing Interstitial Lung Disease, historical and forecasted epidemiology as well as the PF-ILD trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Progressive Fibrosing Interstitial Lung Disease Understanding
Progressive Fibrosing Interstitial Lung Disease (PF-ILD) consists of a diverse group of interstitial lung diseases (ILDs) characterized by a similar clinical phenotype of accelerated respiratory failure, frequent disease exacerbation and earlier mortality.
Interstitial lung disease is believed to be caused by long-term exposure to hazardous materials, such as asbestos or coal dust, or it can be caused by an auto-immune disease such as rheumatoid arthritis. Once lung scarring occurs, it is generally irreversible.
Progressive Fibrosing Interstitial Lung Diseases are composed of Idiopathic Interstitial Pneumonias such as non-specific interstitial pneumonia and unclassifiable interstitial pneumonia, and inhalation lung diseases such as chronic hypersensitivity pneumonia, and connective tissue disease-associated ILD such as rheumatoid arthritis-related ILD and SSc-related ILD, and sarcoidosis and so on. Many interstitial lung diseases (ILDs) are characterized by chronic progressive fibrosis. The type-specific segmentation majorly includes, Idiopathic Interstitial Pneumonias (IIPs), Autoimmune ILDs, Hypersensitivity Pneumonitis, Sarcoidosis, and other ILDs.

Progressive Fibrosing Interstitial Lung Disease Diagnosis
Imaging tests such as X-ray and a high-resolution computed tomography (CT scan), is key to, and sometimes the first step in, the diagnosis of interstitial lung disease. The severity level of Progressive Fibrosing Interstitial Lung Disease is calculated on the basis of FVC score. However, identifying and determining the cause of interstitial lung disease can be challenging, as a large number of disorders fall into this broad category. Hence differential diagnosis is needed.
The differential diagnosis of Interstitial Lung Diseases requires a multidisciplinary approach, usually involving pulmonologist, radiologist, and pathologist. The evaluations include clinical presentation, specific history assessment, smoking status, lung function evaluation, serological test results, imaging and if required, lung biopsy.
Continued in the report…..
Progressive Fibrosing Interstitial Lung Disease Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Interstitial Lung Disease (ILD), Total Diagnosed Prevalent Cases of Interstitial Lung Disease (ILD), Type-specific Diagnosed Prevalent Cases of Interstitial Lung Disease (ILD), Total Diagnosed Prevalent Cases of Progressive Fibrosing Interstitial Lung Disease (PF-ILD), in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan, from 2019 to 2032.
Progressive Fibrosing Interstitial Lung Disease Detailed Epidemiology Segmentation
• In the assessment done , the estimated total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease (PF-ILD) in the 7MM were 322,197 in 2021.
• The highest total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease were accounted by the US in 2021 (166,393 cases), which are expected to show a rise in the future.
• Among the European countries, Germany had the highest diagnosed prevalent cases of PF-ILD with 31,807 cases, followed by the United Kingdom, which had prevalent population of 25,446 in 2021. On the other hand, Spain had the lowest prevalent population (17,834 cases).
• Japan had 31,542 total diagnosed prevalent cases of Progressive Fibrosing Interstitial Lung Disease in 2021, accounting for approximately 10% in 7MM.

Scope of the Report
• The report covers the descriptive overview of Progressive Fibrosing Interstitial Lung Disease, explaining its symptoms, grading, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan.
• The report assesses the disease risk and burden of Progressive Fibrosing Interstitial Lung Disease.
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.

Report Highlights
• 11-Year Forecast of Progressive Fibrosing Interstitial Lung Disease
• 7MM Coverage
• Total Diagnosed Prevalent Cases of Progressive Fibrosing Interstitial Lung Disease

Key Questions Answered
• What are the disease risk and burden of Progressive Fibrosing Interstitial Lung Disease?
• What is the historical Progressive Fibrosing Interstitial Lung Disease patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Progressive Fibrosing Interstitial Lung Disease at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Progressive Fibrosing Interstitial Lung Disease?
• Out of the above-mentioned countries, which country would have the highest prevalent population of Progressive Fibrosing Interstitial Lung Disease during the forecast period (2022–2032)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2022–2032)?

Reasons to buy
The Progressive Fibrosing Interstitial Lung Disease report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM+ Progressive Fibrosing Interstitial Lung Disease epidemiology forecast.
• The Progressive Fibrosing Interstitial Lung Disease epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Progressive Fibrosing Interstitial Lung Disease epidemiology model developed is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 11-year forecast period using reputable sources.

Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of Disease by segmentation
• Factors driving growth in a specific patient population

Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019–2032

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Global Respiratory Disease Testing Industry

  • $ 5450
  • October 2022
  • 158 pages

Abstract: What’s New for 2022? Global competitiveness and key competitor percentage market shares Market presence across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-pee ...

  • World
  • China
  • Respiratory Disease
  • Industry analysis

ref:plp2022

Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on